B. Riley analyst Neil Chatterji raised the firm’s price target on Augmedix to $6.50 from $5.50 and keeps a Buy rating on the shares following the Q2 beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AUGX:
- Augmedix Delivers 47% Revenue Growth and Expanded Gross Margins for Second Quarter of 2023
- AUGX Earnings this Week: How Will it Perform?
- Augmedix to Announce Second Quarter 2023 Financial Results and Host Investor Conference Call on August 7, 2023
- Augmedix extends term loan facility, finalizes terms for line of credit
- Augmedix Extends Term Loan Facility and Finalizes Terms for Equity Line of Credit